Table 3.
Patient outcome, IHC data, and (final) image SUV data
| Outcome and IHC data |
PET image data (final image) |
||||||
|---|---|---|---|---|---|---|---|
| Patient # | Outcome | Histology | CRB | EF5 (% max) | ROI | Volume (cc) | SUV (mean±SD) |
| 1 | DOD (355) | GBM | 100 | 65.2% | Whole lesion | 26.2 | 1.0±0.3 |
| Rostral tumor | 0.8 | 1.2±0.2 | |||||
| Caudal tumor | 1.8 | 0.7±0.1 | |||||
| Normal brain | 5.9 | 0.7±0.1 | |||||
| Muscle | 0.9 | 0.6±0.1 | |||||
| 2 | NED (1,360) | EsoMET | 100 | 8.0% | Whole lesion | 6.0 | 1.0±0.3 |
| Normal brain | 4.2 | 0.9±0.3 | |||||
| Muscle | NA | NA | |||||
| 3 | DOD (599) | GBM | 267 | 20.6% | Whole lesion | 52.4 | 0.9±0.3 |
| Normal brain | 10.0 | 0.7±0.2 | |||||
| Muscle | 1.9 | 0.7±0.2 | |||||
Number in parentheses after outcome is days following EF5 administration
CRB cube reference binding, ROI region of interest, DOD dead of disease, GBM glioblastoma multiforme, NED no evidence of disease, EsoMet esophageal metastasis, NA not enough local muscle tissue for assay